fbpx

breast cancer

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00

Principle Investigator of WHAM study, Professor Martha Hickey, shares study findings

WHAM (What Happens After Menopause?) was a multicentre prospective study investigating the impact of risk reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high-risk women. The ANZGOG supported study assessed the relationship between surgical menopause and [...]

Principle Investigator of WHAM study, Professor Martha Hickey, shares study findings2021-07-28T07:03:34+10:00
Go to Top